Amycretin (Zenagamtide): Mechanism, Trials, and What the Data Actually Shows
Amycretin (Zenagamtide) is a Phase 3 program from Novo Nordisk built around GLP-1/Amylin. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Novo Nordisk
Mechanism
GLP-1/Amylin
Stage
Phase 3
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on Amycretin (Zenagamtide)?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View Amycretin (Zenagamtide) statusCompound facts for search and AI answers
What this Amycretin (Zenagamtide) tracking page answers
Compound
Amycretin (Zenagamtide) from Novo Nordisk
Amycretin (Zenagamtide) is tracked in the dual agonists group.
Mechanism
GLP-1/Amylin
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 3
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Evidence read
Up to 13.1% at 12 weeks in Phase 2 (ongoing)
Amycretin (Zenagamtide) should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as Up to 13.1% at 12 weeks, tied to Phase 2 (ongoing). This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Latest FormBlends pipeline read
Trial program
Phase 2 (ongoing)
Weight loss signal
Up to 13.1% at 12 weeks
Administration
Oral and injectable
Next milestone
2026
Single-molecule GLP-1/amylin co-agonist with exceptionally rapid early weight loss. The oral formulation showed strong results in early data, potentially enabling a monthly oral pill. Phase 1b showed up to 13.1% body weight reduction in just 12 weeks, an unprecedented rate of weight loss for the duration. Oral formulation demonstrated 8.6% at 12 weeks.
Clinical evidence snapshot
What the evidence can and cannot say about Amycretin (Zenagamtide)
Amycretin (Zenagamtide) should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as Up to 13.1% at 12 weeks, tied to Phase 2 (ongoing). This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is Amycretin (Zenagamtide) available now or watchlist only?
Amycretin (Zenagamtide) should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- Amycretin (Zenagamtide)
- Developer
- Novo Nordisk
- Stage
- Phase 3
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is Amycretin (Zenagamtide)?
Amycretin (Zenagamtide) is a phase 3 obesity or metabolic program from Novo Nordisk built around GLP-1/Amylin.
Is Amycretin (Zenagamtide) approved?
No. Amycretin is still a Phase 3 program. It is one of Novo's most important next-wave assets, but it is not yet an approved commercial obesity drug.
When could it matter?
2027 to 2028 is the realistic window if development continues smoothly.
What Amycretin (Zenagamtide) is
Amycretin (Zenagamtide) is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Novo Nordisk is using GLP-1/Amylin as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For Amycretin (Zenagamtide), the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More dual agonists on FormBlends
Frequently asked questions
What is Amycretin (Zenagamtide)?
Amycretin (Zenagamtide) is a Phase 3 obesity or metabolic compound from Novo Nordisk. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does Amycretin (Zenagamtide) work?
Amycretin (Zenagamtide) is being tracked as a GLP-1/Amylin program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is Amycretin (Zenagamtide) available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking Amycretin (Zenagamtide)?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.